Social network
Investors - Ensuring sustainable growth
Investors - Ensuring sustainable growth


Ensuring sustainable growth

Tools content (print, share, increase/decrease text size):


The shareholders committee activities

To allow the committee to be a real link between Sanofi and the individual shareholders it represents, the Investor Relations team regularly informs it about the Company’s business and invites its members to participate in different communication activities. As a result, the committee members learn more about how a leading pharmaceutical company operates and are able to assess the challenges of an efficient shareholder communication.

The committee’s meetings

Every year, the committee meets 3-4 times. Each meeting is an opportunity to:

  • Present and discuss the Company’s news: financial results, product and research pipeline news
  • Discuss the results of past activities and plan those ahead : local shareholder meetings, annual general meeting, shareholding fare Actionaria
  • Discuss communication projects
  • Share ideas on specific initiatives and the global communication strategy

March 2017: Meeting with Serge Weinberg, Chairman of the Board

On March 17, 2017, the Investor Relations team welcomed the newly composed Shareholder committee at Sanofi's headquarters in Paris to present full-year 2016 results and the implementation of the strategic roadmap 2020. This first meeting of the year was also an opportunity to discuss communication projects in 2017 and prepare for the annual general meeting.


Serge Weinberg, Chairman of the Board, joined the group at lunch to discuss Sanofi's achievements in 2016 and answer questions on hot topics, perspectives and dividend policy.


December 2016: Meeting with Jérôme Contamine, Executive Vice President, Chief Financial Officer

On December 14, 2016, the Shareholder Committee gathered at Sanofi's headquarters in Paris to learn more about the 2016 first nine months and discuss news around product launches, study results and share price evolution.
Sanofi CFO Jérôme Contamine joined the committee at lunch and answered questions about the implementation of Sanofi’s strategy.
The Investor Relations team also thanked outgoing members for their commitment to the shareholders commitee.


September 2016: Meeting with Philippe Luscan, EVP, Global Industrial Affairs

On September 23, 2016, the Shareholder Committee gathered at Sanofi's headquarters in Paris to learn more about the first half results of 2016 and discuss news around product launches, study results and share price evolution. The Investor Relations team also presented this year’s setup at the Actionaria shareholder exhibition and the process to renew half of the members of the committee by year-end.


At lunch, the committee had the opportunity to meet Philippe Luscan, Executive Vice-President Global Industrial Affairs and President, Sanofi France. He outlined the company’s ambition to make Sanofi Industrial Affairs the gold standard in the pharmaceutical industry and answered questions on the industrial sites network in France and the world.


June 2016: Visit to Neuville-sur-Saône - the world’s first production facility dedicated to the dengue vaccine

Neuville-sur-Saône - Visit of the Shareholders Committee

On June 22, 2016, the Individual Shareholders Committee (CCAI) visited the Neuville-sur-Saône site, near Lyon, France, the world’s first and only production facility of the dengue vaccine, Dengvaxia®.

Antoine Quin, Head of the Neuville site, presented the ambitious industrial reconversion of the site. Created in 1872 to manufacture artificial colorings and specialized in the chemical production of pharmaceutical active ingredients from the 1950s to 2013, the Neuville site is the third European production center of Sanofi Pasteur, entirely dedicated to the biotechnological production of Dengvaxia®. In 2008, six years prior to the publication of Phase III results demonstrating the efficacy of the dengue vaccine, Sanofi decided to invest €300 million in the transformation of the Neuville facility. The site benefits from the proximity of the Marcy l’Etoile site, the largest vaccines research, development and production center worldwide and the global headquarters of Sanofi Pasteur in Lyon.

More than 200 employees work in Neuville in different industrial units with key expertise for the manufacturing of Dengvaxia®: a vaccine production unit, a unit for the production and distribution of utilities (purified water, compressed air…), another unit for quality control, that could also be used for other control activities of different Sanofi Pasteur vaccines; and a building dedicated to the development and improvement of industrial and analytical processes.

Antoine Quin also highlighted the strategic objective of Sanofi Pasteur: provide endemic countries with 1 billion doses of Dengvaxia® in the next ten years. The Neuville site was designed to be able to quickly supply large volumes of the dengue vaccine, to provide a rapid and massive solution to the countries most affected by dengue.

Thierry Youhanna, production unit head, explains the production process of the vaccine's active ingredient

After the presentation, the CCAI visited the production unit of Dengvaxia®, and had a look at the rooms dedicated to cell and viral culture. Thierry Youhanna, head of this unit, explained the different production steps of the active ingredient of Dengvaxia® which respect the highest quality and safety standards. The committee members were impressed by the complexity of the process, which consists of the production of a very high number of cells that are used to reproduce the live attenuated viruses (four serotypes of the virus are included in the final vaccine). After purification, concentration and filtration the active ingredient (bulk) is ready. Bags containing the bulk are stored at -70°C and transported to another site, Val de Reuil in Upper Normandy, where the final vaccine is produced and packaged.

The Shareholders Committee visits the production unit


March 2016: Meeting with Serge Weinberg, Chairman of the Board

On March 18, 2016, the Investor Relations team welcomed the Shareholder committee at Sanofi's headquarters in Paris to present full-year 2015 results and the strategic roadmap 2020. This first meeting of the year was also an opportunity to discuss communication projects in 2016 and prepare for the annual general meeting.


Serge Weinberg, Chairman of the Board, joined the group at lunch to discuss Sanofi's achievements in 2015 and answer questions on perspectives, dividend policy and new Board members.


September 2015: First meeting with Olivier Brandicourt, CEO

On September 11, 2015, the individual shareholders committee (CCAI) gathered at Sanofi’s Headquarters in Paris to discuss the Company’s performance in the first half of 2015 and share ideas on upcoming communication projects: the creation of a new section dedicated to individual shareholders on the mobile app SANOFI IR, and Sanofi’s upcoming participation at Salon Actionaria 2015, Europe’s largest exhibition for individual shareholders.

At lunch, the CCAI had the opportunity to speak with Jérôme Contamine, Executive Vice President, Chief Financial Officer, and meet Olivier Brandicourt, Chief Executive Officer for the first time.


Olivier Brandicourt and Jérôme Contamine, with members of the CCAI and the Investor Relations team


June 2015: Visit of the Frankfurt production site

On June 5, 2015, the Individual Shareholders Committee (CCAI) went to one of Sanofi’s largest sites: Industriepark Höchst, in Frankfurt, Germany.

The CCAI members and the Investor Relations team were welcomed by members of the Sanofi Germany and Diabetes management team, as the German affiliate and the Global Diabetes division are headquartered on this site. Frankfurt-Höchst is the largest integrated Sanofi site where the complete diabetes product portfolio is manufactured using aseptic state-of-the-art manufacturing technologies. In Frankfurt, the whole value chain for insulins and diabetic peptides is co-located, which means R&D, production of drug substance, drug product and medical devices. All global diabetes injectable products and their medical devices are registered and, historically, all have been produced in Frankfurt.

Matthias Braun, Vice President Industrial Affairs, Chemistry and Biotechnology, and his colleagues presented key facts and figures about Sanofi Germany and the strategic Frankfurt site. They also highlighted the significant contribution of the Company to diabetes care and insulin innovation since 1923: going from the first large-scale production of insulin to the success of Lantus®, the leading insulin brand worldwide, to the launch of Toujeo®, the next generation of basal insulin.

Following the presentations, the CCAI had the opportunity to observe the different steps of insulin production and manufacturing and visited the Solostar® and Toujeo® pen assembly line.

This CCAI meeting was also the opportunity to present Sanofi’s financial performance and share trend in Q1 2015 and discuss the recent Annual General Meeting, which was the first time individual shareholders met with Olivier Brandicourt, Sanofi’s new Chief Executive Officer.


June 2014: Visit of the Tours production site

On June 25, 2014, the Sanofi Investor Relations team invited the Individual Shareholders Committee to join their annual site visit to the Tours production facility.

Pascal Bourin, Head of the Tours site, presented the main activities of the plant which was established in 1967. Tours is specialized in the production of solid products – tablets and capsules - in Cardiovascular, Internal Medicine, Central Nervous System, Generics and Consumer Healthcare areas and exports 80% of its production to Europe, Asia, Africa, the Middle East, Latin America, the United States, Australia and Japan. The Aprovel® and Allegra®/Telfast® ranges, Tildiem®, Xatral® and Ambien®/Stilnox® are among the main products made onsite.

The Tours site also houses an Industrial Support Center and the Central Anti-Counterfeit Laboratory (CACL) of Sanofi, created in 2008 to ensure the quality of Sanofi products for patients. In her presentation, Nathalie Tallet, Head of the Industrial Support Center and the CACL, highlighted that the CACL had analyzed more than 20,000 suspect products since 2008, more than 4,000 of which in 2013, and played an increasing role in the global fight against counterfeit drugs.

After a visit of the production and packaging lines, the Committee observed the work of the experts of the CACL, notably their use of advanced high-tech equipment to analyze samples of counterfeit products.

The day concluded with a meeting with the Investor Relations team dedicated to first-quarter results of 2014, the share performance and the shareholders’ general meeting.

Learn more about Sanofi’s committment to the fight against countefeit medicines :


June 2013: Visit of the Le Trait production site

Every year, the CCAI has the opportunity to visit one of Sanofi’s production or research facilities to learn more about the different businesses. On June 13, 2013, the committee members gathered with the Investor Relations team at the Le Trait production site in Normandy.

Created in 1969, the production site is dedicated to the delivery of pre-filled syringes, eye drops and nasal sprays, supplying more than 57 countries, including the United States and Japan. It is one of our flagship sites for the anti-thrombotic Clexane® / Lovenox®. It supplies more than 50% of the worldwide production of Lovenox®. Le Trait also produces anti-allergic products such as the eye drops and nasal spray Opticron®/Intal®.

Since 2004, the Le Trait plant has been handling the filling and packaging operations for the production of seasonal influenza vaccines for the Northern hemisphere and an infant meningitis vaccine for the Japanese market, in collaboration with Sanofi Pasteur.

Le Trait is the “Technology Lead Site/Launch Plant” for pre-filled syringe technology products, notably for the monoclonal antibodies under development: alirocumab (anti-PCSK9) and sarilumab (anti IL-6R).

Le Trait also houses an Industrial Development and Innovation Center.

After a meeting with the Investor Relations team, the CCAI followed a presentation on the history and activities of Le Trait by site head Pierre-Jean Tissier, and visited the filling, inspection and packaging lines of Lovenox® syringes.  


July 2012: Meeting with Sanofi Pasteur, Merial and Genzyme and visit of the Genzyme bioproduction site

The Individual Shareholders' Committee met on the site of Sanofi Pasteur in Lyon (Rhône-Alpes, France) on the morning of Monday, July 2nd, 2012. The Committee was welcomed by the representatives of Sanofi Pasteur and Merial who presented their respective activities. In the afternoon, the Committee visited the new Genzyme bioproduction site in Lyon, this French city being the center of a dynamic community of life sciences with Sanofi Pasteur, Genzyme and Merial.

Sanofi Pasteur, the Vaccines division of Sanofi, is a world leader in five domains: flu vaccines, pediatric vaccinal combinations, booster vaccines, meningitis vaccines and the vaccines dedicated to travelers and for the endemic zones. Sanofi Pasteur produces more than a billion vaccine doses per year, intended to fight 20 bacterial and viral diseases (26 types of vaccines in total are marketed in the world). More than 500 million people are inoculated every year globally.

Merial - the Animal Health division of Sanofi - created in 1997 through the merger of Rhône Mérieux and MSD AgVet veterinary activities, is a world leader in Animal Health. In 2009, Merial became a wholly-owned subsidiary of Sanofi. Merial is world number 1 in companion animals, number 1 in rabies vaccines, and also number 1 in vaccines against foot-and-mouth disease (FMD) and bluetongue fever. Finally, the expertise of Merial and the quality of its products are recognized by governments and wildlife conservation agencies around the world.

Genzyme is one of the world's leading biotech companies and has pioneered the development and delivery of transformative therapies in the class of rare genetic diseases known as lysosomal storage disorders. Now Genzyme represents the center of excellence at Sanofi in rare diseases and multiple sclerosis. The Individual Shareholders Committee had the opportunity to visit the bioproduction site in the Gerland district of Lyon where Genzyme set up its new manufacturing unit of polyclonal antibody Thymoglobuline® intended for the prevention of transplant rejection in transplanted patients. These antibodies are used as selective immunosuppressive therapy of the lymphocytes T in organ transplant or bone marrow. Produced exclusively in Lyon, this biomedicine is registered in 64 countries in the world (Europe, Japan and the United States). Genzyme made a commitment to a HQE® approach (High Quality Environmental).


October 2011: Visit of the Jacob Production unit on the Vitry-sur-Seine site

On October 12, 2011, the Shareholders’ Committee met on the Vitry-sur-Seine site (Val de Marne) in the Southeastern suburbs of Paris. The Committee was welcomed by Hubert Loetscher, Head of the Production Center, who presented the site’s history and future evolutions. Created in 1908 by Rhône Poulenc, the Vitry platform comprises Production and Research & Development activities. The industrial activities include Process Development Biotechnology, and historically, the production of pharmaceutical active ingredients using biochemical and chemical technologies for therapeutic areas such as cardiovascular, oncology, anti-infectives, anti-inflammatories and neuroleptics.

Today, the Vitry-sur-Seine site focuses on two production activities. The first one is the production of high activity molecules, such as cabazitaxel, the active ingredient of the new cancer treatment Jevtana®. The second one is the production of cell culture. With the announcement in 2008 of the Biolaunch project, the site becomes a biotechnological production platform, from laboratory, to pilot to industrial production stage.

The Shareholders’ Committee had the opportunity to visit the new Jacob Production unit, an investment of close to 200 million euros that represents a new cell culture production platform for the Company. This cell culture unit will develop and produce monoclonal antibodies as from 2012. Monoclonal antibodies are complex proteins that offer new possibilities for better targeted and more effective treatments with fewer side effects. 


June 2010: Visit of the Val de Reuil Vaccine site

On June 3, 2010, the Individual Shareholders Committee met at the Val de Reuil vaccine production site in Upper Normandy in northern France. After a working meeting with the Investor Relations team, the Committee attended a presentation by sanofi pasteur and toured Val de Reuil, one of sanofi pasteur’s historical production sites.

The Val de Reuil site is the company’s worldwide distribution site and has the largest influenza vaccine production capacity in the world. During its tour with the site manager, the Committee discovered how vaccines are formulated and distributed in liquid form.


© Sanofi 2004-2017 - All rights reserved - Update: April 11, 2017

  • Site complies with W3C WCAG 2.0 (new window, in english)